Similar companies
Income Statement (USD)
Q1 '24 | QoQ | |
---|---|---|
Revenue | 663M | 10.6% |
Gross Profit | 605M | 11.2% |
Cost of Revenue | 217M | 7.7% |
Operating expense | 249M | 11.9% |
Net Income | 307M | 41.2% |
EBITDA | 427M | 31.7% |
Balance Sheet (USD)
Q1 '24 | QoQ | |
---|---|---|
Total Assets | 6.5B | 9.4% |
Total Liabilities | 1.16B | 2.1% |
Total Equity | 5.34B | 10.8% |
Shares Outstanding | 44M | 6% |
Cash Flow (USD)
Q1 '24 | QoQ | |
---|---|---|
Cash from operations | 377M | 149.8% |
Cash from investing | 735M | 1646.6% |
Cash from financing | -1.07B | 1050.9% |
EPS
Financial Highlights for United Therapeutics in Q1 '24
United Therapeutics reported a revenue of 663M, which is a 10.6% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 605M, marking a 11.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 217M, a 7.7% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 249M, showing a -11.9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 307M, showing a 41.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 427M, showing a 31.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for United Therapeutics with growth in revenue, gross profit, and net income.